Treatments such as ibrutinib and venetoclax, which target the Bruton tyrosine kinase (BTK) pathway and the B-cell lymphoma 2 (BCL-2) protein respectively, have proven to be efficacious as targeted therapies for previously untreated patients with chronic lymphocytic leukemia (CLL). For patients who have progressed on existing therapies, novel BTK inhibitors such as pirtobrutinib and MK1026 represent promising alternative treatment options.
In today’s podcast, Jennifer Woyach, MD and Adam Kittai, MD, Ohio State University College of Medicine in Columbus, OH, provide their perspectives on key themes and topics in the treatment and management of CLL. They evaluate findings from the CAPTIVATE, GLOW and CLL13 clinical trials, long-term follow up data of the ALLIANCE A041202 and SEQUOIA trials, novel agents and the role of MRD in CLL.
This interview took place at the 63rd ASH Annual Meeting and Exposition Congress, Atlanta, GA, 2021.
Recent updates in CML: treatment strategies, clinical trials, and novel agents
iwNHL Session II: Understanding and harnessing the immune microenvironment against lymphoma
iwAL 2022 Session II: Novel treatment strategies in ALL
The role of the innate immune system in MDS
iwAL 2022 Session I: The standard of care in AML in 2022
iwNHL 2022 Session I: Advances in the treatment of T-cell lymphoma
ISA 2022: meeting highlights and recent updates in amyloidosis
Highlights from IMS 2022: managing high-risk & frail patients with myeloma and the prognostic value of MRD
Highlights from the 2022 Texas MPN Workshop: early intervention, disease progression & future targets
iwMDS 2022: Key highlights
Identifying high-risk myeloma and improving treatment strategies in these patients
Improving the efficiency of drug approvals in MDS
Highlights from the 2022 Texas MPN Workshop: advances in MPN treatment
The need for more effective first-line therapies in MDS
Myeloma 2022: day two highlights
The promise of CAR-T therapy in CLL and challenges in the field
Clonal hematopoiesis and pre-MDS states
T-cell engagers in multiple myeloma: current challenges and future outlooks
High-risk MDS: unmet needs and future treatment approaches
The importance of patient-reported outcomes in CAR-T recipients
Create your
podcast in
minutes
It is Free
Good Mood Revolution
Good Nurse Bad Nurse
The Relaxback UK Show
On Call With Dr. Anselm Anyoha
The Peter Attia Drive
The Doctor’s Farmacy with Mark Hyman, M.D.